Rutgers Center of Excellence in Rapid Surveillance of Tobacco
Project Number1U01CA278695-01
Contact PI/Project LeaderDELNEVO, CRISTINE D
Awardee OrganizationRUTGERS BIOMEDICAL AND HEALTH SCIENCES
Description
Abstract Text
ABSTRACT
The 2009 Tobacco Control Act (TCA) gave the FDA authority to regulate tobacco products to protect public
health but initially extended only to cigarettes. By the time other products were deemed under FDA authority in
2016, the tobacco landscape had changed dramatically, making modern tobacco surveillance increasingly
complex. Unfortunately, the cigarette-centric tobacco surveillance systems in the US have been slow to
respond to these changes. Even after formal calls for improvements in smokeless tobacco and cigar
measurement more than 20 years ago, standardized measures of these products remain sparse and
insufficient. Moreover, despite numerous early warning signals, questions about JUUL did not appear on major
national surveys such as National Youth Tobacco Survey until 2019, two full years after it became the top-
selling ENDS brand on the market and ENDS use among youth had reached concerning levels. Indeed, rapid
assessment and response to changes in the tobacco market are essential to informing and evaluating FDA’s
current and pending regulatory actions, including proposed product standards (e.g., banning menthol), pending
marketing authorizations for e-cigarettes, and the modified risk tobacco products (MRTPs) pathway. Therefore,
informed by a conceptual framework which draws upon a traditional public health surveillance perspective as
well as FDA’s Sentinel Initiative, this U01 proposal assembles a large collaborative network, which includes a
network of six sentinel states that triangulates multiple data sources to establish the Center for Rapid
Surveillance of Tobacco (CRST). The CRST aims to perform rapid surveillance of: 1) tobacco product
marketing, to generate signals of interest; 2) the tobacco product marketplace, to generate and refine signals
of interest; and 3) changes in tobacco product use behaviors, to generate, refine, and evaluate signals of
interest. We will implement an optimal rapid surveillance system of tobacco that will enhance FDA’s regulation
of tobacco products using a range of methods and subject matter experts to rapidly assess meaningful
changes in tobacco marketing, the tobacco marketplace, and tobacco use. The team assembled has deep
experience with tobacco regulatory science, surveillance and analyses of these data. We also have extensive
experience overseeing multi-site projects in collaboration with federal partners that support our ability to carry
out the administrative aspects of CRST. Our ongoing engagement with FDA CTP, federal partners, and
CASEL and deep knowledge of FDA’s regulatory authority and processes ensure that we will not only conduct
rapid surveillance, but anticipate changes in the market via early signal detection, and deliver meaningful data
to inform FDA’s activities and support a substantial public health impact. In doing so, we will establish a new
paradigm of tobacco surveillance, serve as a resource on surveillance methods and measures, support
evolutions in traditional surveillance measures, and meaningfully advance the field of tobacco regulatory
science.
Public Health Relevance Statement
PROJECT NARRATIVE
Rapid assessment and response to the increasingly diverse tobacco market are essential to informing and
evaluating FDA’s current and pending regulatory actions, including proposed product standards, pending
marketing authorizations for e-cigarettes, and the modified risk tobacco products (MRTPs) pathway. This U01
proposal assembles a large collaborative network that triangulates multiple data sources to establish the
Center for Rapid Surveillance of Tobacco (CRST), which will perform surveillance of tobacco product
marketing, the tobacco product marketplace, and tobacco use behaviors, transforming tobacco surveillance to
be rapid, comprehensive, and coordinated, with salient findings fed immediately into traditional data collection
systems. By identifying and evaluating signals in a timely fashion, the CRST will generate critical actionable
information about changes in tobacco products which can inform FDA’s regulation of tobacco products leading
to a substantial public health impact.
No Sub Projects information available for 1U01CA278695-01
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 1U01CA278695-01
Patents
No Patents information available for 1U01CA278695-01
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 1U01CA278695-01
Clinical Studies
No Clinical Studies information available for 1U01CA278695-01
News and More
Related News Releases
No news release information available for 1U01CA278695-01
History
No Historical information available for 1U01CA278695-01
Similar Projects
No Similar Projects information available for 1U01CA278695-01